{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:15:18Z","timestamp":1790622918832,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T00:00:00Z","timestamp":1317600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (RCT)<\/jats:p>\n                    <jats:p>Level of Evidence\u20031b<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Male lower urinary tract symptoms are often attributed to bladder outlet obstruction secondary to benign prostatic hyperplasia and treated with drugs targeting the prostate. However, many men with storage lower urinary tract symptoms may not respond adequately to these agents.<\/jats:p>\n                    <jats:p>Antimuscarinics, with or without an \u03b1\u2010blocker, may be effective for the treatment of the storage symptoms of overactive bladder in some men.<\/jats:p>\n                    <jats:p>Flexible\u2010dose fesoterodine as an add\u2010on treatment significantly improved urinary frequency and symptom bother, but not urgency episodes (primary endpoint), versus add\u2010on placebo and was well tolerated in men with persistent overactive bladder symptoms despite receiving \u03b1\u2010blocker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To evaluate flexible\u2010dose fesoterodine vs placebo in men with persistent overactive bladder (OAB) symptoms despite receiving \u03b1\u2010blocker treatment<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUBJECTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>This was a double\u2010blind, 12\u2010week, flexible\u2010dose trial.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Men with persistent storage symptoms (\u22658 micturitions and \u22653 urgency episodes per 24\u2003h) after receiving an \u03b1\u2010blocker for \u22656 weeks were randomized to add\u2010on fesoterodine 4\u2003mg or placebo, with optional dose escalation to 8\u2003mg at week 4 and reduction back to 4\u2003mg at week 8 (or matching placebo adjustments).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Subjects completed 3\u2010day diaries, International Prostate Symptom Score (IPSS), Overactive Bladder Questionnaire (OAB\u2010q), Patient Perception of Bladder Condition (PPBC), and Urgency Perception Scale (UPS) at baseline and weeks 4 and 12.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>\n                            A total of 943 men were randomized and received at least one dose of study treatment (fesoterodine,\n                            <jats:italic>n<\/jats:italic>\n                            = 471; placebo,\n                            <jats:italic>n<\/jats:italic>\n                            = 472).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Among these, 251 (53%) in the fesoterodine group and 300 (64%) in the placebo group requested dose escalation at week 4 and 35 (7%) and 15 (3%) requested dose reduction at week 8. Changes from baseline to week 12 in urgency episodes (primary endpoint) in the fesoterodine (\u22123.2) and placebo (\u22122.9) groups were not significantly different (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.196), but improvements in micturitions (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.009) and OAB\u2010q symptom bother score (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.007) were significantly greater with fesoterodine.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            At week 4, significantly greater improvements in micturitions (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.006), severe urgency episodes (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.006), IPSS storage score (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.022), OAB\u2010q symptom bother score (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.004), and OAB\u2010q health\u2010related quality of life (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.041), but not urgency episodes (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.062), were observed with add\u2010on fesoterodine.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Dry mouth (fesoterodine, 21%; placebo, 6%) and constipation (fesoterodine, 6%; placebo, 2%) were the most common adverse events. Dysuria and urinary retention were reported by 3% and 2% of subjects, respectively, in the fesoterodine add\u2010on group vs 1% and &lt;1% of subjects, respectively in the placebo add\u2010on group. One subject in each group had acute urinary retention requiring catheterization.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Flexible\u2010dose fesoterodine was well tolerated as an add\u2010on treatment in men with persistent storage symptoms.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Changes in urgency episodes at week 12 (primary endpoint) and many secondary endpoints were not significantly different between fesoterodine and placebo add\u2010on treatment; however, improvements in frequency and symptom bother were significantly greater with fesoterodine.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>These data suggest that there remains a limited understanding of the optimal evaluation and treatment of men with LUTS.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2011.10624.x","type":"journal-article","created":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T08:47:25Z","timestamp":1317631645000},"page":"1831-1840","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Add\u2010on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving \u03b1\u2010blocker treatment for lower urinary tract symptoms"],"prefix":"10.1111","volume":"109","author":[{"given":"Steven A.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus G.","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,3]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.02.026"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07601.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08371.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-002-0095-3"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro1060"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0b013e32831505fe"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.05039.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.19.2319"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20798"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000067541.73285.eb"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0b013e32832ce8a4"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02611.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.09.007"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.007"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21005"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36966-5"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016370925601"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05345.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.11.026"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.08.023"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1002"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.06.067"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.032"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09359.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00655-4"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00654-2"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.06.051"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02035.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.09.018"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10624.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10624.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:41:45Z","timestamp":1761759705000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10624.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,3]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10624.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10624.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,3]]},"assertion":[{"value":"2011-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}